Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Summit Therapeutics' potential pipeline could help drive strong stock performances for a long time. Is it worth it to buy a ...

One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...

Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...

ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

Serendipity Space, a pioneering space-tech company developing microgravity-based pharmaceutical manufacturing solutions, has raised its pre-seed round from Campus Fund. The investment will accelerate ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...

Merck’s stock fell 1.77% to $80.93 while the market gained, despite rising 5.26% over the past month. The company’s upcoming ...